Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus HALDOL SOLUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus HALDOL SOLUTAB.
CHLORPROMAZINE HYDROCHLORIDE INTENSOL vs HALDOL SOLUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpromazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits antagonism at serotonin 5-HT2, histamine H1, alpha-1 adrenergic, and muscarinic receptors, contributing to its sedative, antiemetic, and hypotensive effects.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
Oral: 25-50 mg 2-3 times daily, up to 1000 mg/day in severe psychosis. IM: 25-50 mg every 1-4 hours until controlled, then switch to oral.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
None Documented
None Documented
15-30 hours; prolonged in elderly and hepatic impairment; active metabolites (e.g., 7-hydroxychlorpromazine) have longer half-lives (up to 12-24 hours)
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (~20-30%)
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Category C
Category C
Antipsychotic
Antipsychotic